Literature DB >> 23686318

Small nucleolar RNA-derived microRNA hsa-miR-1291 modulates cellular drug disposition through direct targeting of ABC transporter ABCC1.

Yu-Zhuo Pan1, Amy Zhou, Zihua Hu, Ai-Ming Yu.   

Abstract

Multidrug resistance-associated protein 1 (MRP1/ABCC1) is an important membrane transporter that contributes to cellular disposition of many endobiotic and xenobiotic agents, and it can also confer multidrug resistance. This study aimed to investigate the role of human noncoding microRNA-1291 (hsa-miR-1291) in regulation of ABCC1 and drug disposition. Bioinformatics analyses indicated that hsa-miR-1291, localized within the small nucleolar RNA H/ACA box 34 (SNORA34), might target ABCC1 3'-untranslated region (3'UTR). Using splinted ligation small RNA detection method, we found that SNORA34 was processed into hsa-miR-1291 in human pancreatic carcinoma PANC-1 cells. Luciferase reporter assays showed that ABCC1 3'-UTR-luciferase activity was decreased by 20% in cells transfected with hsa-miR-1291 expression plasmid, and increased by 40% in cells transfected with hsa-miR-1291 antagomir. Furthermore, immunoblot study revealed that ABCC1 protein expression was sharply reduced in hsa-miR-1291-stably transfected PANC-1 cells, which was attenuated by hsa-miR-1291 antagomir. The change of ABCC1 protein expression was associated with an alternation in mRNA expression. In addition, hsa-miR-1291-directed downregulation of ABCC1 led to a greater intracellular drug accumulation and sensitized the cells to doxorubicin. Together, our results indicate that hsa-miR-1291 is derived from SNORA34 and modulates cellular drug disposition and chemosensitivity through regulation of ABCC1 expression. These findings shall improve the understanding of microRNA-controlled epigenetic regulatory mechanisms underlying multidrug resistance and interindividual variability in pharmacokinetics.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23686318      PMCID: PMC3781368          DOI: 10.1124/dmd.113.052092

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  43 in total

1.  Cajal body-specific small nuclear RNAs: a novel class of 2'-O-methylation and pseudouridylation guide RNAs.

Authors:  Xavier Darzacq; Beáta E Jády; Céline Verheggen; Arnold M Kiss; Edouard Bertrand; Tamás Kiss
Journal:  EMBO J       Date:  2002-06-03       Impact factor: 11.598

2.  Clinical role of multidrug resistance protein 1 expression in chemotherapy resistance in early-stage breast cancer: the Austrian Breast and Colorectal Cancer Study Group.

Authors:  Martin Filipits; Gudrun Pohl; Margaretha Rudas; Otto Dietze; Sigurd Lax; Renate Grill; Robert Pirker; Christoph C Zielinski; Hubert Hausmaninger; Ernst Kubista; Hellmut Samonigg; Raimund Jakesz
Journal:  J Clin Oncol       Date:  2005-02-20       Impact factor: 44.544

3.  A Cajal body-specific pseudouridylation guide RNA is composed of two box H/ACA snoRNA-like domains.

Authors:  Arnold M Kiss; Beáta E Jády; Xavier Darzacq; Céline Verheggen; Edouard Bertrand; Tamás Kiss
Journal:  Nucleic Acids Res       Date:  2002-11-01       Impact factor: 16.971

4.  Multidrug resistance in small cell lung cancer: expression of P-glycoprotein, multidrug resistance protein 1 and lung resistance protein in chemo-naive patients and in relapsed disease.

Authors:  Nadja Triller; Peter Korosec; Izidor Kern; Mitja Kosnik; Andrej Debeljak
Journal:  Lung Cancer       Date:  2006-08-24       Impact factor: 5.705

5.  Association of high-level MRP1 expression with poor clinical outcome in a large prospective study of primary neuroblastoma.

Authors:  Michelle Haber; Janice Smith; Sharon B Bordow; Claudia Flemming; Susan L Cohn; Wendy B London; Glenn M Marshall; Murray D Norris
Journal:  J Clin Oncol       Date:  2006-04-01       Impact factor: 44.544

6.  MicroRNA regulates the expression of human cytochrome P450 1B1.

Authors:  Yuki Tsuchiya; Miki Nakajima; Shingo Takagi; Takao Taniya; Tsuyoshi Yokoi
Journal:  Cancer Res       Date:  2006-09-15       Impact factor: 12.701

7.  Breast cancer resistance protein BCRP/ABCG2 regulatory microRNAs (hsa-miR-328, -519c and -520h) and their differential expression in stem-like ABCG2+ cancer cells.

Authors:  Xin Li; Yu-Zhuo Pan; Gail M Seigel; Zi-Hua Hu; Min Huang; Ai-Ming Yu
Journal:  Biochem Pharmacol       Date:  2011-01-08       Impact factor: 5.858

8.  Down-regulation of ATP-binding cassette C2 protein expression in HepG2 cells after rifampicin treatment is mediated by microRNA-379.

Authors:  Sierk Haenisch; Sandra Laechelt; Henrike Bruckmueller; Anneke Werk; Andreas Noack; Oliver Bruhn; Cornelia Remmler; Ingolf Cascorbi
Journal:  Mol Pharmacol       Date:  2011-05-03       Impact factor: 4.436

9.  Human box H/ACA pseudouridylation guide RNA machinery.

Authors:  Arnold M Kiss; Beáta E Jády; Edouard Bertrand; Tamás Kiss
Journal:  Mol Cell Biol       Date:  2004-07       Impact factor: 4.272

10.  Direct detection of small RNAs using splinted ligation.

Authors:  Patricia A Maroney; Sangpen Chamnongpol; Frédéric Souret; Timothy W Nilsen
Journal:  Nat Protoc       Date:  2008       Impact factor: 13.491

View more
  38 in total

Review 1.  MicroRNA Pharmacoepigenetics: Posttranscriptional Regulation Mechanisms behind Variable Drug Disposition and Strategy to Develop More Effective Therapy.

Authors:  Ai-Ming Yu; Ye Tian; Mei-Juan Tu; Pui Yan Ho; Joseph L Jilek
Journal:  Drug Metab Dispos       Date:  2015-11-13       Impact factor: 3.922

2.  Combination therapy with bioengineered miR-34a prodrug and doxorubicin synergistically suppresses osteosarcoma growth.

Authors:  Yong Zhao; Mei-Juan Tu; Yi-Feng Yu; Wei-Peng Wang; Qiu-Xia Chen; Jing-Xin Qiu; Ai-Xi Yu; Ai-Ming Yu
Journal:  Biochem Pharmacol       Date:  2015-10-27       Impact factor: 5.858

3.  Potential role of epigenetic mechanisms in the regulation of drug metabolism and transport.

Authors:  Magnus Ingelman-Sundberg; Xiao-Bo Zhong; Oliver Hankinson; Sudheer Beedanagari; Ai-Ming Yu; Lai Peng; Yoichi Osawa
Journal:  Drug Metab Dispos       Date:  2013-08-05       Impact factor: 3.922

4.  Chimeric MicroRNA-1291 Biosynthesized Efficiently in Escherichia coli Is Effective to Reduce Target Gene Expression in Human Carcinoma Cells and Improve Chemosensitivity.

Authors:  Mei-Mei Li; Balasubrahmanyam Addepalli; Mei-Juan Tu; Qiu-Xia Chen; Wei-Peng Wang; Patrick A Limbach; Janine M LaSalle; Su Zeng; Min Huang; Ai-Ming Yu
Journal:  Drug Metab Dispos       Date:  2015-05-01       Impact factor: 3.922

Review 5.  The effects of microRNA on the absorption, distribution, metabolism and excretion of drugs.

Authors:  Y He; J R Chevillet; G Liu; T K Kim; K Wang
Journal:  Br J Pharmacol       Date:  2014-12-01       Impact factor: 8.739

6.  miR-7 modulates chemoresistance of small cell lung cancer by repressing MRP1/ABCC1.

Authors:  Huanxin Liu; Xiaoxia Wu; Jie Huang; Juan Peng; Linlang Guo
Journal:  Int J Exp Pathol       Date:  2015-06-24       Impact factor: 1.925

7.  N-methylnicotinamide and nicotinamide N-methyltransferase are associated with microRNA-1291-altered pancreatic carcinoma cell metabolome and suppressed tumorigenesis.

Authors:  Hui-Chang Bi; Yu-Zhuo Pan; Jing-Xin Qiu; Kristopher W Krausz; Fei Li; Caroline H Johnson; Chang-Tao Jiang; Frank J Gonzalez; Ai-Ming Yu
Journal:  Carcinogenesis       Date:  2014-08-12       Impact factor: 4.944

8.  miR-1268a regulates ABCC1 expression to mediate temozolomide resistance in glioblastoma.

Authors:  Yaomin Li; Yawei Liu; Jing Ren; Shengze Deng; Guozhong Yi; Manlan Guo; Songren Shu; Liang Zhao; Yuping Peng; Songtao Qi
Journal:  J Neurooncol       Date:  2018-06-06       Impact factor: 4.130

Review 9.  Advances and challenges in studying noncoding RNA regulation of drug metabolism and development of RNA therapeutics.

Authors:  Baitang Ning; Dianke Yu; Ai-Ming Yu
Journal:  Biochem Pharmacol       Date:  2019-09-10       Impact factor: 5.858

10.  RNA Drugs and RNA Targets for Small Molecules: Principles, Progress, and Challenges.

Authors:  Ai-Ming Yu; Young Hee Choi; Mei-Juan Tu
Journal:  Pharmacol Rev       Date:  2020-10       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.